A selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats

Related Experiment Video

Updated: Jan 30, 2026

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

6.9K

Julio C B Ferreira1,2, Juliane C Campos3, Nir Qvit4

  • 1Department of Anatomy, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, 05508-000, SP, Brazil. jcesarbf@usp.br.

Nature Communications
|January 20, 2019
PubMed

Insights

Heart failure involves elevated beta II protein kinase C (βIIPKC), which damages mitochondria by phosphorylating mitofusin 1 (Mfn1). Targeting this interaction with SAMβA peptide protects heart cells and improves function in heart failure models.

Area of Science:

  • Cardiovascular Biology
  • Mitochondrial Dynamics
  • Protein Kinase Signaling

Background:

  • Beta II protein kinase C (βIIPKC) activity is elevated in heart failure.
  • βIIPKC contributes to the pathology of failing hearts.

Purpose of the Study:

  • Investigate the role of βIIPKC in mitochondrial dysfunction in heart failure.
  • Determine if targeting the Mfn1-βIIPKC interaction can be a therapeutic strategy.

Main Methods:

  • Assessed βIIPKC localization and mitofusin 1 (Mfn1) phosphorylation at serine 86 in heart failure models.
  • Utilized βIIPKC siRNA, βIIPKC inhibitor, and a peptide antagonist (SAMβA) to disrupt the Mfn1-βIIPKC interaction.
  • Evaluated mitochondrial morphology, function, cell viability, and cardiac contractility.

Main Results:

  • βIIPKC phosphorylates Mfn1 at serine 86, leading to mitochondrial fragmentation and dysfunction.
  • βIIPKC inhibition or siRNA mitigated mitochondrial fragmentation and cell death.
  • SAMβA selectively antagonized Mfn1-βIIPKC association, protecting cardiac myocytes from stress-induced death.
  • SAMβA treatment improved mitochondrial morphology and function, enhancing cardiac contractility in a rat heart failure model.

Conclusions:

  • The Mfn1-βIIPKC interaction is a key driver of mitochondrial dysfunction and cell death in heart failure.
  • Targeting this interaction with SAMβA shows therapeutic potential for heart failure patients.

More Related Videos

A Rat Lung Transplantation Model of Warm Ischemia/Reperfusion Injury: Optimizations to Improve Outcomes07:37

A Rat Lung Transplantation Model of Warm Ischemia/Reperfusion Injury: Optimizations to Improve Outcomes

Published on: October 28, 2021

3.5K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
907
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
877
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
332
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
963